Sibrafiban|172927-65-0|-陌孚医药/Medlife

您当前的位置：

Sibrafiban

目录号: PL14881 纯度: ≥99%

CAS No. :172927-65-0

商品编号	规格	价格	会员价
PL14881-5mg	5mg	¥3709.09	请登录
PL14881-10mg	10mg	¥5934.55	请登录
PL14881-25mg	25mg	¥11869.09	请登录
PL14881-50mg	50mg	询价	询价
PL14881-100mg	100mg	询价	询价
PL14881-10mM*1mLinDMSO	10mM*1mLinDMSO	¥4080.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Sibrafiban
英文名称	Sibrafiban
英文别名	Acetic acid,2-[[1-[(2S)-2-[[4-[(Z)-amino(hydroxyimino)methyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-,ethyl ester;Acetic acid,2-[[1-[(2S)-2-[[4-[(Z)-amino(hydroxyimino)methyl]benzoyl]amino]-1-oxopropyl]-4-pip...;ethyl 2-[1-[(2S)-2-[[4-[(Z)-N'-hydroxycarbamimidoyl]benzoyl]amino]propanoyl]piperidin-4-yl]oxyacetate;SIBRAFIBAN;((1-(2-((4-(amino(hydroxyimino)methyl)benzoyl)amino)-1-oxopropyl)-4-piperidinyl)oxy)acetic acid ethyl ester;Acetic acid, ((1-(2-((4-(amino(hydroxyimino)methyl)benzoyl)amino)-1-oxopropyl)-4-piperidinyl)oxy)-, ethyl ester, (S-(Z))-;Ethyl (Z)-((1-(N-((p-hydroxyamidino)benzoyl)-L-alanyl)-4-piperidyl)oxy)acetate;ethyl {[1-(N-{[4-(hydroxycarbamimidoyl)phenyl]carbonyl}-L-alanyl)piperid;Ro 48-3657;Sibrafiban [USAN:INN:BAN];UNII-YUE443B0NF;WBNUCLPUOSXSNJ-UHFFFAOYSA-N;Sibrafiban
Cas No.	172927-65-0
分子式	C₂₀H₂₈N₄O₆
分子量	420.46
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	Sibrafiban (RO 48-3657) 是一种 Ro 44-3888 的具有口服活性的，非肽，双重前药，是一种选择性的糖蛋白 IIb/IIIa 受体 (glycoprotein IIb/IIIa receptor) 拮抗剂。Sibrafiban 可抑制血小板聚集。
生物活性	Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-prodrug of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation.
性状	Solid
IC50 & Target[1][2]	Glycoprotein IIb/IIIa receptor
体外研究(In Vitro)	The effects of site occupancy by Sibrafiban on platelet activation are assessed using P-selectin expression, fibrinogen binding and microaggregate formation. Sibrafiban inhibits ADP and TRAP-stimulated fibrinogen binding and microaggregate formation in a concentration-dependent manner, whereas P-selectin expression is relatively unaltered. A decrease in site occupancy from peak to trough of Sibrafiban does not result in increased activation of platelets. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	The effects of Ro 44-3888 on the platelet aggregation response to ADP (17 μmol) and on cutaneous bleeding times is determined in 8 rhesus monkeys given Sibrafiban 0.25 mg/kg/day or 0.5 mg/kg/day orally for 8 days. The maximum inhibition of ex vivo platelet aggregation and prolongation of bleeding time by Ro 44-3888 are dose dependent. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. M Dooley, et al. Sibrafiban. Drugs. 1999 Feb;57(2):225-30; discussion 231-2. [2]. B Wittke, et al. Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. Br J Clin Pharmacol. 2000 Mar;49(3):231-9. [3]. Jeffrey T Billheimer, et al. Effects of glycoprotein IIb/II

溶解度数据	In Vitro: DMSO : 33.33 mg/mL (79.27 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation